II. Mechanism
- Synthetic Hallucinogen (2C) acting at 5-HT2A receptor (potent Serotonin 2A receptor Agonists)
- Phenethylamine pharmacore increases Neurotransmitter levels with Sympathomimetic effects
- Originally developed in 2003 as Serotonin 2A receptor Agonist as traceable agent for PET Scan
III. Preparations
- Formulations
- Most common formulation of three produced: 25I-NBOMe
- Forms include liquid, powder, capsule, tablet, spray
- Used orally most frequently (mixed with solvent on blotting paper)
- Also used sublingual, intranasal, rectal, smoked or injected
- Typically sold for $7-10 per dose
- Street Names
- N-Bomb
- Smiles
IV. Pharmacokinetics
- Minimum effective dose: 50 mcg SL
- Onset: 20 minutes
- Duration: 3-13 hours
V. Symptoms
- Sympathomimetic effects and Hallucinogenic effects
- Desired Effects
- Hallucinations (similar to Ecstasy)
- Dissociation
- Euphoria
VI. Labs
- Serum Creatine Kinase
- White Blood Cell Count (Leukocytosis)
- Serum Glucose (Hyperglycemia)
- Serum transaminases (increased)
- Serum Creatinine (increased)
VII. Adverse effects
- Cardiovascular effects (Serotonin Syndrome)
- Neuropsychiatric effects
- Agitation and aggression (85% of patients)
- Hyperthermia
- Delirium
- Paranoia
- Altered Mental Status
- Apnea
- Hyperreflexia
- Clonus
- Seizures (75%)
- Miscellaneous
- Tongue Paresthesias (related to blotting paper contact reaction)
VIII. Complications
- Hyperthermia
- Pulmonary Edema
- Death
- Status Epilepticus (with anoxic brain injury)
- Acute Kidney Injury
-
Serotonin Syndrome
- NBOMe has very high affinity for Serotonin receptors
IX. Management
- Benzodiazepines
- IV Fluids
- Prevent or treat Rhabdomyolysis
- Cooling measures
- Manage hyperthermia
X. References
- Bersani (2014) Biomed Res Int 2014: 734749
- Haynes, Meadors and Yuan (2016) Crit Dec Emerg Med 30(2): 3-9
- Laskowski (2015) J Med Toxicol 11(2):237-41 +PMID:25387562 [PubMed]